Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.53 |
| ▸ | ITGAV | P06756 | 8/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 8/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7514763 | 1.00 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7375503 | 0.93 | ITGB3 (0.46) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2784510 | 0.86 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6418707 | 0.86 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2785184 | 0.86 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7402752 | 0.85 | ITGB3 (0.74) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7402755 | 0.85 | ITGB3 (0.74) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6418531 | 0.85 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6418535 | 0.85 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6419571 | 0.85 | ITGB3 (0.57) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020123487-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-09-05 | — | — | US | disclosed |
| US-20020019387-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-02-14 | — | — | US | disclosed |
| EP-1023073-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999015178-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123487-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ITGB3 248/4885ITGAV 240/4885ITGA2B 158/4885 |
| US-20020019387-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ITGB3 248/4885ITGAV 240/4885ITGA2B 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.